Drug Trial Radar · NCT00094367
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
Last checked: Nov 19, 2026Latest source record: Sep 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
900
Actual
Start
Jul 2004
Primary completion
Oct 2005
Study completion Oct 2005
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 18, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.
Conditions
- HIV Infection
Interventions
Abacavir/LamivudineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The occurrence of treatment-limiting adverse events after starting study drugs.
Locations
178 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Arleta, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
Panorama City, California
GSK Investigational Site
Paramount, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Salinas, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Santa Rosa, California
GSK Investigational Site
Tarzana, California
GSK Investigational Site
Tarzana, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Glastonbury, Connecticut
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Norwalk, Connecticut
GSK Investigational Site
Stamford, Connecticut
GSK Investigational Site
Stratford, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Coral Gables, Florida
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.